AHL Partners’s Acceleron Pharma XLRN Stock Holding History

AHL Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-12,517	Closed	-$453K	–	1234
2016 Q3	$453K	Buy	+12,517	New	+$415K	0.02%	867

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

AHL Partners's XLRN Position: Q4 2016 in Review

AHL Partners sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 12,517 shares — an estimated $453K sold.

AHL Partners first reported a position in XLRN in Q3 2016 and held it in 1 quarter. The position peaked at $453K in Q3 2016. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

AHL Partners reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
AHL Partners sold 12,517 Acceleron Pharma shares in Q4 2016, an estimated $453K.
AHL Partners first reported a position in Acceleron Pharma in Q3 2016 and held it in 1 quarter.
AHL Partners's Acceleron Pharma position peaked at $453K in Q3 2016.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.